Stellenwert der pelvinen Lymphadenektomie in der Therapie des Prostata- und Blasenkarzinoms

Zusammenfassung

Die Rationale einer Staging-Lymphadenektomie in der chirurgischen Therapie des Prostata- und Harnblasenkarzinoms mit kurativer Intention besteht in der verlässlichen Diagnose lymphonodulärer Mikrometastasen, um die Sinnhaftigkeit einer möglichen postoperativen adjuvanten Therapie abschätzen zu können. Zielsetzung der vorliegenden Arbeit ist eine kritische Beurteilung der publizierten Daten, um mögliche Standards der LA definieren zu können. Das Ausmaß der pelvinen Lymphadenektomie im Rahmen der radikalen Prostatektomie (RPE) wird kontrovers diskutiert. Die anatomisch adäquate, extendierte pelvine Lymphadenektomie (EPLA) schließt die Lymphknotenstationen der A. iliaca communis bis zur Ureterkreuzung, der A. iliaca externa und interna sowie der Fossa obturatoria ein. Gegenüber der Standard-LA wird die Anzahl dissezierter Lymphknoten signifikant gesteigert, die Frequenz positiver Lymphknoten nahezu verdoppelt. Die Frequenz pathohistologisch detektierter Mikrometastasen ist sowohl beim klinisch lokalisierten als auch beim lokal fortgeschrittenen PCA signifikant höher als durch präoperative Nomogramme vorhergesagt. Auch wenn derzeit keine prospektiv randomisierten klinischen Studien den therapeutischen Benefit der EPLA beweisen, könnten Patienten mit einer minimalen Lymphknotenmetastasierung profitieren. Aus einer Vielzahl von Studien geht hervor, dass das Risiko der PCA-spezifischen Mortalität bei fehlender lymphonodulärer Metastasierung bzw. 1 - 2 befallenen Lymphknoten nicht signifikant voneinander differiert. Da sich die therapieassoziierte Morbidität der EPLA nicht gegenüber der Standard-LA unterscheidet, sollte die EPLA bei allen Patienten im Rahmen der RPE bevorzugt werden. Im Rahmen der radikalen Zystektomie wurde die anatomische Ausdehnung der pelvinen Lymphadenektomie bis dato noch nicht standardisiert, obwohl ein Zusammenhang zwischen Ausmaß der LA und dem progressionsfreien Überleben existiert. Verschiedene retro- und prospektive Mappingstudien zur anatomischen Verteilung lymphonodulärer Mikrometastasen zeigten, dass die Lymphknotendissektion entlang der A. iliaca communis bis zur aortalen Bifurkation, der Aa. Iliaca externa und interna sowie der Fossa obturatoria 80 % aller betroffenen Lymphknotenmetastasen erfasst. Weiter kranial gelegene Filiae sind überwiegend nur bei intrapelviner Metastasierung darstellbar, so dass eine Ausdehnung der LA bis in den Bereich der A. mesenterica inferior nur bei positivem Schnellschnitt indiziert erscheint. Die EPLA beim Harnblasenkarzinom resultiert in der Verbesserung des progressionsfreien Überlebens, nicht jedoch des tumorspezifischen oder Gesamtüberlebens.

Abstract

The rationale for locoregional staging lymphadenectomy in prostate cancer lies in the accurate diagnosis of occult micrometastases in order to stratify patients who might benefit from adjuvant therapeutic measures. In prostate cancer, extended pelvic lymphadenectomy (EPLA) including the lymphatic tissue along the common iliac region with the ureteral crossing as cranial margin, external and internal iliac region and the obturator fossa, has been shown to increase the yield of both total lymph nodes and lymph node metastases significantly. The total number of lymph nodes removed is about 2- to 3-fold higher and the frequency of micrometastatic lymph nodes is approximately 2-fold higher compared to standard lymphadenectomy. Furthermore, the frequency of observed positive lymph nodes in clinically localized and locally advanced prostate cancer is significantly higher than predicted by nomograms such as Partin tables and CART analysis. Although there are no prospective randomized trials demonstrating a survival benefit associated with EPLA, there might be an advantage for those with minimal lymph node involvement. Progression-free survival is significantly improved in patients undergoing EPLA with a 35 % benefit compared to standard lymphadenectomy. Various studies have documented an equal risk of cancer-associated mortality in patients with no or only 1 - 2 positive lymph nodes. Since the surgery-associated morbidity of EPLA is not increased as compared to standard lymphadenectomy, EPLA should be favoured at least for all intermediate and high risk patients undergoing radical prostatectomy; in low risk patients the option of EPLA has to be discussed thoroughly. For the future, ongoing prospective trials have to demonstrate a clear benefit in terms of biochemical-free and cancer-specific survival. With regard to muscle-invasive bladder cancer, it has been shown that lymph node dissection along the external, internal and common iliac artery and obturator fossa achieves accurate data for a valid locoregional staging. Only if frozen section analysis reveals metastatic deposits along these areas an extension of the lymphadenectomy including the aortic bifurcation up to the inferior mesenteric artery seems to be of additional diagnostic value. Various studies have demonstrated that extended pelvic lymphadenectomy results in an improvement of progression-free survival, however no significant benefit with regard to cancer-specific and overall survival has been demonstrated. Nevertheless, pelvic lymphadenectomy remains one of the most significant prognosticators with regard to relapse rates as has been demonstrated recently and, therefore, it should be performed thoroughly and anatomically adequate.

Schlüsselwörter

Prostatakarzinom - muskelinvasives Blasenkarzinom - Staging-lymphadenektomie - lokoregionales Staging - radikale Prostatektomie - tumorfreie Überlebenszeit

Key words

Prostate cancer - muscle invasive bladder cancer - staging lymphadenectomy - locoregional staging - radical prostatectomy - progression-free survival

Literatur

• 1 Gil-Vernet J M. Prostate cancer: anatomical and surgical considerations.  Brit J Urol. 1996;  78 161-168
• 2 Crawford E D, Batuello J T, Snow P, Gamito E J, McLeod D G, Partin A W, Stone N, Montie J, Stock R, Lynch J, Brandt J. The use of artificial intelligence technology to predict lymph node spread in men with clinically localized prostate carcinoma.  Cancer. 2000;  88 2105-2109
• 3 Batuello J T, Gamito E J, Crawford E D, Han M, Partin A W, McLeod D G. et al . Artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer.  Urology. 2001;  57 481-485
• 4 Partin A W, Kattan M W, Subing E NP, Walsh P C, Wojno K J, Oesterling J E. et al . Combination of prostate-specific antigen, clinical stage, and Gleason sum to predict pathological stage of localized prostate cancer: a multi-institutional update.  JAMA. 1997;  277 1445-1451
• 5 Algari M, Colton M D, Seidmon E J, Greenberg R E, Hanno P M. The staging pelvic lymphadenectomy: implication as an adjunctive procedure for clinically localized prostate cancer.  J Urol. 1997;  162 243-246
• 6 Narayan P, Fournier G, Gajendran V, Leidich R, Lo R, Wolf J S, Jacob G, Nicolaisen G, Palmer K, Freiha F. Utility of preoperative serum prostate specific antigen concentration and biopsy Gleason score in predicting risk of pelvic lymph node metastases in prostate cancer.  Urology. 1994;  44 519-524
• 7 Bluestein D L, Bostwick D G, Bergstralh E J, Oesterling J E. Eliminating the need for bilateral pelvic lymphadenectomy in select patients with prostate cancer.  J Urol. 1994;  151 1315-1320
• 8 Conrad S, Graefen M, Pichlmaier U, Henke R P, Hammerer P G, Huland H. Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastasis in patients with clinically localized prostate cancer.  J Urol. 1998;  159 2023
• 9 Conrad S, Graefen M, Pichlmaier U, Henke R P, Ebersdobler A, Hammerer P G, Huland H. Prospective validation of an algoithm with systematic sextant biopsy to predict lymph node metastasis in patients with clinically localized prostate cancer.  J Urol. 2002;  167 521
• 10 Haese A, Epstein J I, Huland H, Partin A W. Validation of a biopsy based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostatic carcinoma.  Cancer. 2002;  95 1016
• 11 Naya Y, Babaian R J. The predictors of pelvic lymph node metastasis at radical retropubic prostatectomy.  J Urol. 2003;  170 2306-2310
• 12 Heidenreich A, Knobloch R von, Varga Z, Hofmann R. Extended pelvic lymphadenectomy in men undergoing radical retropubic prostatectomy - data on > 300 cases.  Proc ASCO. 2003;  22 409s (Abstract), -409s (Abstract), 4612
• 13 Burkhard F C, Bader P, Schneider E, Markwald R, Studer U E. Reliability of preoperative values to determine the need for lymphadenectomy in patients with prostate cancer and meticulous lymph node dissection.  Eur Urol. 2002;  42 84-90
• 14 Schuhmacher M, Burkhardt F, Markwalder R, Studer U. Lymph nodes metastases in patients with prostate cancer and with a PSA < 10 ng/ml.  Eur Urol Suppl. 2004;  3 17, -17 57 (Abstract)
• 15 Weckermann D, Wawroschek F, Harzmann R. Is there a need for pelvic lymph node dissection in low risk prostate cancer patients prior to definitive local therapy?.  Eur Urol. 2005;  47 45-51
• 16 Allaf M E, Palapattu G S, Trock B J, Carter H B, Walsh P C. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer.  J Urol. 2004;  172 1840-1844
• 17 Weingärtner K, Ramaswamy A, Bittinger A, Gerharz E W, Vöge D, Riedmiller H. Anatomical basis for pelvic lymphadenectomy in prostate cancer: results of an autopsy study and implications for the clinic.  J Urol. 1996;  156 1969-1971
• 18 Heidenreich A, Knobloch R von, Varga Z. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy in prostate cancer: high incidence of lymph node metastases.  J Urol. 2001;  167 1681-1684
• 19 Bader P, Burkhard F C, Markwalder R, Studer U E. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?.  J Urol. 2003;  169 849-854
• 20 Dillioglugil J F, Leibman B D, Leibman N S, Kattan M W, Rosas A L, Scardino P T. Risk factors for complications and morbidity after radical retropubic prostatectomy.  J Urol. 1997;  157 1760-1767
• 21 Wolf Jr J S. Indications, technique, and results of laparoscopic pelvic lymphadenectomy.  J Endourol. 2001;  15 427-435
• 22 Parkin J, Keeley Jr F X, Timoney A G. Laparoscopic lymph node sampling in locally advanced prostate cancer.  BJU Int. 2002;  89 14-17
• 23 Solberg A, Angelsen A, Bergan U, Haugen O A, Viset T, Klepp O. Frequency of lymphoceles after open and laparoscopic pelvic lymph node dissection in patients with prostate cancer.  Scand J Urol Nephrol. 2003;  37 218-221
• 24 Guillonneau B, Cappele O, Martinez J B, Navarra S, Vallancien G. Robotic assisted, laparoscopic pelvic lymph node dissection in humans.  J Urol. 2001;  165 1078-1081
• 25 Finelli A, Gill I S, Desai M M, Moinzadeh A, Magi-Galluzzi C, Kaouk J H. Laparoscopic extended pelvic lymphadenectomy for bladder cancer: technique and initial results.  J Urol. 2004;  172 1809-1812
• 26 Fergany A, Kupelian P A, Levin H S, Zippe C D, Reddy C, Klein E A. No difference in biochemical failure reates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients.  Urology. 2000;  56 92-95
• 27 Meng M V, Carroll P R. When is pelvic lymph node dissection necessary before radical prostatectomy? A decision analysis.  J Urol. 2000;  164 1235-1240
• 28 El-Galley R ES, Keane T E, Petros J A, Sanders W H, Clarke H S, Cotsonis G A, Graham S D. Evaluation of staging lymphadenectomy in prostate cancer.  Urology. 1998;  52 663-667
• 29 Salomon L, Hoznek A, Lefrere-Belda M A, Bellot J, Chopin D K, Abbou C C. Nondissection of pelvic lymph nodes does not influence the results of perineal radical prostatectomy in selected patients.  Eur Urol. 2000;  37 297-300
• 30 Bishoff J T, Reyes A, Thompson I M, Harris M J, Clair S R, Gomella L, Butzin C A. Pelvic lymphadenectomy can be omitted in selected patients with carcinoma of the prostate: development of a system of patient selection.  Urology. 1995;  45 270-273
• 31 Cheng L, Zincke H, Blute M L, Bergstralh E J, Scherer B, Bostwick D G. Risk of prostate cancer death in patients with lymph node metastasis.  Cancer. 2001;  91 66-71
• 32 Hull G W, Rabbani F, Abbas F, Wheeler T M, Kattan M W, Scardino P T. Cancer control with radical prostatectomy alone in 1000 consecutive patients.  J Urol. 2002;  167 528-534
• 33 Bader P, Spahn M, Huber R, Echtle D, Frohneber D. Limited lymph node dissection in prostate cancer may miss lymph node metastases and determines outcome of apparently PNO prostate cancer.  Eur Urol Suppl 3:. 2004;  No 2, 16 55
• 34 Messing E, Manola J, Sarosdy M, Wilding G, Crawford E D, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node positive prostate cancer.  N Engl J Med. 1999;  341 1781-1788
• 35 Messing E M, Manola J, Sarosdy M. et al . Immediate hormonal therapy versus observation after radical prostatectomy and pelvic lymphadenectomy for node positive prostate cancer: at 10 years results of EST3886.  Proc ASCO. 2004;  22 399s, -399s 4570 (Abstract)-57 (Abstract)
• 36 Wawroschek F, Vogt H, Weckermann D, Wagner T H, Harzmann R. Radioisotope guided pelvic lymph node dissection for prostate cancer.  J Urol. 2001;  166 1715-1719
• 37 Wawroschek F, Wagner T, Hamm M, Weckermann D, Vogt H, Gordijn R, Harzmann R. The influence of serial sections, immunohistochemistry, and extension of pelvic lymph node dissection on the lymph node detection in clinically localized prostate cancer.  Eur Urol. 2003;  43 132-136
• 38 Takashima H, Egawa M, Imao T, Fukuda M, Yokoyama K, Namiki M. Validity of sentinel lymph node concept for patients with prostate cancer.  J Urol. 2004;  171 2268-2271
• 39 Heidenreich A, Varga Z, Knobloch R von, Barth P. Sentinel lymph node scintigraphy (SLNS) for diagnostic improvement of pelvic lymphadenectomy in prostate cancer.  J Urol 2002. (Suppl);  167 348, -348 1380 (Abstract)
• 40 Polasczik T J, Manyak M J, Haseman M K, Gurganus R T, Rogers B, Maguire R T, Partin A W. Comparison of clinical staging algorithms and ¹¹¹Indium-Capromab Pendetide Immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients.  Cancer. 1999;  85 1586-1592
• 41 Sodee D B, Malguria N, Faulhaber P, Resnick M I, Albert J, Bakale G. and the Prostacint Imaging Centers . Multicenter Prostacint imaging findings in 2154 patients with prostate cancer.  Urology. 2000;  56 988-993
• 42 Grossmann H B, Natale R B, Tangen C M. et al . Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.  N Engl J Med. 2003;  349 859-866
• 43 Herr H W, Faulkner J R, Grossman H B. et al . Surgical factors influence bladder cancer outcomes: a cooperative group report.  J Clin Oncol. 2004;  22 2781-2789
• 44 Herr H, Lee C, Chang S, Lerner S. for the Bladder Cancer Collaborative Group . Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer: a collaborative group report.  J Urol. 2004;  171 1823-1828
• 45 Mills R D, Turner W H, Fleischmann A, Markwalder R, Thalmann G N, Studer U E. Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy.  J Urol. 2001;  166 19-23
• 46 Herr W H, Bochner B H, Dalbagni G. et al . Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer.  J Urol. 2003;  167 1295-1297
• 47 Leissner J, Hohenfellner R, Thüroff J W, Wolf H K. Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder: significance for staging and prognosis.  BJU Int. 2000;  85 817-821
• 48 Stein J P, Cai J, Groshen S, Skinner D G. Risk factors for patients with pelvic lymph node metastases following radical cystectomy with en-bloc pelvic lymphadenectomy: the concept of lymph node density.  J Urol. 2003;  170 35
• 49 Abdel-Latif M, Abol-Eneim H, El-Baz M, Ghoneim M A. Nodal involvement in bladder cancer cases treated with radical cystectomy: incidence and prognosis.  J Urol. 2004;  172 85-89
• 50 Herr W H. Superiority of ratio based lymph node staging for bladder cancer.  J Urol. 2003;  169 943
• 51 Borchner B H, Herr H W, Reuter V E. Impact of separate versus en bloc lymph node dissection in the number of lymph nodes retrieved in cystectomy specimens.  J Urol. 2001;  166 2295
• 52 Poulsen A L, Horn T, Steven K. Radical cystectomy: extending limits of pelvic lymph node dissection improves survival for patients with bladder cancer confined to the bladder wall.  J Urol. 1998;  160 2015-2019
• 53 Leissner J, Allhoff E P, Hohenfellner R, Wolf H K. Ranking of pelvic lymphadenectomy in therapy and prognosis of carcinoma of the bladder.  Akt Urol. 2003;  34 392-397
• 54 Leissner J, Ghoneim M A, Abol-Eneim H. et al . Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study.  J Urol. 2004;  171 139-144
• 55 Bochner B H, Cho D, Herr H W. et al . Prospectively packaged lymph node dissections with radical cystectomy: evaluation of node count variability and node mapping.  J Urol. 2004;  172 1286-1290
• 56 Abol-Enein H, El-Baz M, Abd El-Hameed M A, Abdel-Latif M, Ghoneim M A. Lymph node involvement in patients with bladder cancer treated by radical cystectomy: a patho-anatomical study - a single center experience.  J Urol. 2004;  172 1818-1821